Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis

Lancet

Volumn 354, Issue 9195, 1999, Pages 2063-2068

  Eskola, Juhani ^a   Ward, Joe ^b   Dagan, Ron ^f   Goldblatt, David ^c   Zepp, Fred ^d   Siegrist, Claire Anne ^e  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e UNIVERSITY OF GENEVA   (Switzerland)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOLOGICAL ADJUVANT;

ANTIBODY RESPONSE; BACTERIAL INFECTION; DRUG EFFICACY; HUMAN; IMMUNOLOGICAL MEMORY; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0033547607     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)04377-9     Document Type: Review

References (41)

1. Peltola H., Käyhty H., Virtanen M., Mäkelä P.H. Prevention of Haemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med. 310:1984;1561-1566.
2. Käyhty H., Karanko V., Peltola H., Mäkelä P.H. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and response to reimmunisation: no evidence of immunologic tolerance of memory. Pediatrics. 74:1984;857-865.
3. Schneerson R., Barrera O., Sutton A., Robbins J.B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 152:1980;361-376.
4. Eskola J., Ölander R.M., Hovi T., Litmanen L., Peltola S., Käyhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet. 384:1996;1688-1692.
5. Dagan R., Igbarai K., Piglansky L.et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole-cell pertussis pentavalent vaccine. Pediatr Infect Dis J. 16:1997;1113-1121.
6. Mills E., Gold R., Thipphawong J.et al. Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus b conjugate vaccine administered to infants at two, four and six months of age. Vaccine. 16:1998;576-585.
7. Aristegui J., Dal-Ré R., Garrote E., González A., Arrate J.P., Pérez A. Assessment of the immunogenicity and reactogenicity of a quadrivalent diphtheria, tetanus, acellular pertussis and hepatitis B (DTPa-HBV) vaccine administered in a single injection with Haemophilus influenzae type b conjugate vaccine, to infants at 2, 4 and 6 months of age. Vaccine. 16:1998;1976-1984.
8. Dagan R., Eskola J., Leclerc C., Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun. 66:1998;2093-2098.
9. Frasch C. Haemophilus influenzae type b conjugate and combination vaccines. Clin Immunother. 4:1995;376-386.
10. Ambrosino D.M., Landesman S.H., Gorham C.C., Siber G.R. Passive immunization against disease due to Haemophilus influenzae type b: concentrations of antibody to capsular polysaccharide in high-risk children. J Infect Dis. 153:1986;1-7.
11. Santosham M., Reid R., Ambrosino D.M.et al. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. N Engl J Med. 317:1987;923-929.
12. Robbins J.B., Parke J.C., Schneerson R., Whisnant J.K. Quantitative measurement of "natural" and immunisation-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res. 7:1973;103-110.
13. Käyhty H., Peltola H., Karanko V., Mäkelä P.H. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 147:1983;1100.
14. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 149:1984;1034-1035.
15. Goldblatt D., Miller E., McCloskey N., Cartwright K. Immunological response to conjugate vaccines in infants: follow up study. BMJ. 316:1998;1570-1571.
16. Booy R., Heath P.T., Slack M.P.E., Begg N., Moxon E.R. Vaccine failures after primary immunisation with Haemophilus influenzae type b conjugate vaccine without booster. Lancet. 349:1997;1197-1202.
17. Decker M.D., Edwards K.M., Bradley R., Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr. 120:1992;184-189.
18. Madore D.V., Johnson C.L., Phipps D.C.et al. Safety and immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in infants aged 15 to 23 months. Pediatrics. 86:1990;527-534.
19. Miller M.A., Meschievitz C.K., Ballanco G.A., Daum R.S. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period. Pediatrics. 95:1995;522-527.
20. Pichichero M.E., Latiolais T., Bernstein D.I.et al. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants. Pediatr Infect Dis J. 16:1997;863-870.
21. Ferreccio C., Clemens J., Avendano A.et al. The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J. 10:1991;764-777.
22. Avendano A., Ferreccio C., Lagos R.et al. Haemophilus influenzae type b polysaccharide protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J. 12:1993;638-643.
23. Clemens J., Brenner R., Rao M. Interactions between PRP-T vaccines against Haemophilus influenzae type b and conventional infant vaccines. Ann NY Acad Sci. 754:1995;255-266.
24. Granoff D.M., Holmes S.J., Osterholm M.T.et al. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J Infect Dis. 168:1993;663-671.
25. Zepp F., Schmitt H.J., Kaufhold A.et al. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b PRP (Hib) boosters in children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine. Eur J Pediatr. 156:1997;18-24.
26. Clements D.A., Rouse J.B., London W.L.et al. Haemophilus b (Hib) vaccine in infants. Pediatr Res. 20:1986;307.
27. Käyhty H., Eskola J., Peltola H., Saarinen L., Mäkelä P.H. High antibody responses to booster doses of either Haemophilus influenzae type b capsular polysaccharide or conjugate vaccines after primary immunization with conjugate vaccine. J Infect Dis. 165:1992;165-166. (suppl).
28. Käyhty H, Saarinen L, Ronnberg P-R, Tillikainen R, Eskola J. Long term persistence of immunity evoked by Hib conjugate vaccine. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, California, 1995 (abstr G9).
29. Pichichero M.E., Passador S. Administration of combined diphtheria and tetanus toxoids and pertussis vaccine, hepatitis B vaccine, and Haemophilus influenzae type b (Hib) vaccine to infants and response to a booster dose of Hib conjugate vaccine. Clin Infect Dis. 25:1998;1378-1384.
30. Amir J., Scott M.G., Nahm M.H., Granoff D.M. Bactericidal and opsonic activity of IgG1 and IgG2 anticapsular antibodies to Haemophilus influenzae type b. J Infect Dis. 162:1990;163-171.
31. Schlesinger Y., Granoff D.M. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. JAMA. 267:1992;1489-1494.
32. Lucas A.H., Granoff D.M. Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type b polysaccharide-protein conjugates. J Immunol. 154:1995;4195-4202.
33. Schmitt H.J., Zepp F., Müschenborn S.et al. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus toxoid and acellular pertussis vaccine for primary and for booster immunizations. Eur J Pediatr. 157:1998;208-214.
34. Kauppi M., Eskola J., Käyhty H. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. Pediatr Infect Dis J. 14:1995;286-294.
35. Huang H.-F., Greenberg D.P., Wong V.K.et al. Mucosal immunity in infants immunized with H. influenzae type b (Hib) conjugate vaccines. Pediatr Res. 41:1997;47.
36. Kauppi M., Saarinen L., Käyhty H. Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats. J Infect Dis. 167:1993;365-371.
37. Peltola H., Käyhty H., Sivonen A., Mäkelä P.H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics. 60:1977;730-737.
38. Takala A.K., Eskola J., Leinonen M.et al. Reduction in oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis. 164:1991;982-986.
39. Barbour M.L. Conjugate vaccines and the carriage of Haemophilus influenzae type b. Emerg Infect Dis. 2:1996;176-182.
40. Adegbola R.A., Mulholland E.K., Secka O., Jaffar S., Greenwood B.M. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. Influenzae type b among Gambian children. J Infect Dis. 177:1998;1758-1761.
41. Galil K., Singleton R., Levine O.S.et al. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J Infect Dis. 179:1999;101-106.